YD Bio Limited Ordinary Shares (YDES)Stock Price & Financial Statements
AboutBreeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.Show more
- Revenue $510K +45.8%
- EBITDA -$1M -18252.9%
- Net Income -$1M -10509.7%
- EPS (Diluted) -0.56 -280100.0%
- Gross Margin 30.44% -30.5%
- EBITDA Margin -265.93% -12490.7%
- Operating Margin -286.45% -10085.3%
- Net Margin -276.58% -7241.6%
- ROE -42.69% -17761.9%
- ROIC -63.31% -47750.1%
- Debt/Equity 0.00 -99.8%
- Interest Coverage -1893.69 -41131.6%
Key Insights
Based on financial data analysisStrengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 94.1% through buybacks
Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM-
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-
EPS CAGR
10Y-
5Y-
3Y-
TTM-
ROCE
10Y Avg-9.94%
5Y Avg-9.94%
3Y Avg-15.97%
Latest-44.14%
Peer Comparison
Diagnostics and Omics Tools| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 VCYTVeracyte, Inc. | 2.88B | 36.27 | 44.23 | 16.01% | 12.83% | 5.07% | 4.4% | 0.03 |
 ASBPWAspire Biopharma Holdings, Inc. | 178.9K | 0.02 | -0.01 | -16351.77% | ||||
 VRAXVirax Biolabs Group Limited | 1.55M | 0.21 | -0.11 | -95.95% | -78.62% | -234.24% | 0.07 | |
 CDIOCardio Diagnostics Holdings, Inc. | 141.46M | 5.26 | -0.57 | 104.45% | -415.16% | -80.38% | 0.10 | |
 AIMDAinos, Inc. | 7.24M | 1.51 | -0.97 | -83.02% | -132.32% | -148.9% | 0.77 | |
 IMDXInsight Molecular Diagnostics Inc. | 95.47M | 5.47 | -1.17 | 25.15% | -13.81% | -14.81% | ||
 SEERSeer, Inc. | 103.2M | 1.85 | -1.33 | -8.13% | -486.02% | -29.19% | 0.08 | |
 ASBPAspire Biopharma Holdings, Inc. | 62.88M | 1.32 | -5.08 | -16351.99% |
Compare YDES vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 350.13K | 510.36K |
| Revenue Growth % | - | - | - | - | 45.76% |
| Cost of Goods Sold | 0 | 0 | 0 | 196.69K | 355K |
| COGS % of Revenue | - | - | - | 56.17% | 69.56% |
| Gross Profit | 0 | 0 | 0 | 153.44K | 155.36K |
| Gross Margin % | - | - | - | 43.82% | 30.44% |
| Gross Profit Growth % | - | - | - | - | 1.25% |
| Operating Expenses | 344.22K | 1.72M | 2.32M | 163.29K | 1.62M |
| OpEx % of Revenue | - | - | - | 46.64% | 316.89% |
| Selling, General & Admin | 344.22K | 1.72M | 2.32M | 160.56K | 1.13M |
| SG&A % of Revenue | - | - | - | 45.86% | 220.71% |
| Research & Development | 0 | 0 | 0 | 0 | 491.35K |
| R&D % of Revenue | - | - | - | - | 96.28% |
| Other Operating Expenses | 0 | 0 | 0 | 2.73K | -493 |
| Operating Income | -344.22K | -1.72M | -2.32M | -9.85K | -1.46M |
| Operating Margin % | - | - | - | -2.81% | -286.45% |
| Operating Income Growth % | - | -400.36% | -34.88% | 99.58% | -14746.45% |
| EBITDA | -2.54M | 8.7M | 3.79M | -7.39K | -1.36M |
| EBITDA Margin % | - | - | - | -2.11% | -265.93% |
| EBITDA Growth % | - | 442.99% | -56.45% | -100.2% | -18252.87% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 2.45K | 104.73K |
| EBIT | -2.54M | 8.7M | 3.79M | 19.79K | -1.39M |
| Net Interest Income | 178 | 764 | 813 | -1.85K | 11.04K |
| Interest Income | 178 | 764 | 813 | 290 | 11.81K |
| Interest Expense | 0 | 0 | 0 | 2.14K | 772 |
| Other Income/Expense | -2.19M | 10.43M | 6.11M | 27.5K | 75.45K |
| Pretax Income | -2.54M | 8.7M | 3.79M | 17.65K | -1.39M |
| Pretax Margin % | - | - | - | 5.04% | -271.67% |
| Income Tax | 0 | 0 | 2.09K | 4.09K | 25.08K |
| Effective Tax Rate % | 100% | 100% | 99.94% | 76.83% | 101.81% |
| Net Income | -2.54M | 8.7M | 3.79M | 13.56K | -1.41M |
| Net Margin % | - | - | - | 3.87% | -276.58% |
| Net Income Growth % | - | 442.99% | -56.48% | -99.64% | -10509.73% |
| Net Income (Continuing) | -2.54M | 8.7M | 3.79M | 13.56K | -1.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17 | 0.59 | 0.41 | 0.00 | -0.56 |
| EPS Growth % | - | 447.06% | -30.51% | -99.95% | - |
| EPS (Basic) | -0.17 | 0.59 | 0.41 | 0.00 | -0.56 |
| Diluted Shares Outstanding | 14.63M | 14.63M | 9.29M | 70.1M | 4.15M |
| Basic Shares Outstanding | 14.63M | 14.63M | 9.29M | 70.1M | 4.15M |
| Dividend Payout Ratio | - | - | - | - | - |
Balance Sheet
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 830.77K | 129.56K | 202.71K | 271.72K | 3.47M |
| Cash & Short-Term Investments | 693.82K | 5.4K | 14.13K | 87.1K | 3.13M |
| Cash Only | 693.82K | 5.4K | 14.13K | 87.1K | 3.13M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 18.07K | 98.43K | 262.8K |
| Days Sales Outstanding | - | - | - | 102.61 | 187.95 |
| Inventory | 0 | 0 | 0 | 69.4K | 37.34K |
| Days Inventory Outstanding | - | - | - | 128.8 | 38.39 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 116.76M | 117.93M | 17.73M | 49.49K | 3.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | 14.3K | 88.08K |
| Fixed Asset Turnover | - | - | - | 24.48x | 5.79x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 2.68M |
| Long-Term Investments | 116.73M | 117.93M | 17.73M | 10.62K | 10.53M |
| Other Non-Current Assets | 23.29K | 0 | 0 | 0 | -9.9M |
| Total Assets | 117.59M | 118.06M | 17.93M | 321.21K | 6.86M |
| Asset Turnover | - | - | - | 1.09x | 0.07x |
| Asset Growth % | - | 0.4% | -84.81% | -98.21% | 2036.98% |
| Total Current Liabilities | 302.22K | 2M | 5.55M | 298.22K | 263.06K |
| Accounts Payable | 0 | 0 | 0 | 17.98K | 26.74K |
| Days Payables Outstanding | - | - | - | 33.36 | 27.5 |
| Short-Term Debt | 0 | 0 | 0 | 34.32K | 290 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 302.22K | 2M | 5.55M | 344 | 0 |
| Current Ratio | 2.75x | 0.06x | 0.04x | 0.91x | 13.18x |
| Quick Ratio | 2.75x | 0.06x | 0.04x | 0.68x | 13.04x |
| Cash Conversion Cycle | - | - | - | 198.05 | 198.84 |
| Total Non-Current Liabilities | 17.51M | 7.11M | 1.18M | 2.2M | 10.92K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 5.68K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.46K |
| Other Non-Current Liabilities | 17.51M | 7.11M | 1.18M | 2.2M | 3.77K |
| Total Liabilities | 17.81M | 9.11M | 6.74M | 298.22K | 273.98K |
| Total Debt | 0 | 0 | 0 | 47.58K | 22.55K |
| Net Debt | -693.82K | -5.4K | -14.13K | -39.52K | -3.11M |
| Debt / Equity | - | - | - | 2.07x | 0.00x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | -0.00x | -0.00x | - | - |
| Interest Coverage | - | - | - | -4.59x | -1893.69x |
| Total Equity | 99.78M | 108.96M | 11.2M | 22.99K | 6.59M |
| Equity Growth % | - | 9.2% | -89.72% | -99.79% | 28560.72% |
| Book Value per Share | 6.82 | 7.45 | 1.20 | 0.00 | 1.59 |
| Total Shareholders' Equity | 99.78M | 108.96M | 11.2M | 22.99K | 6.59M |
| Common Stock | 115M | 115M | 17.73M | 105.2K | 144.18K |
| Retained Earnings | -15.22M | -6.52M | -6.53M | -515.48K | -1.93M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 47.21K | 45.07K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -253.63K | -688.41K | -3.02M | -55.66K | -1.84M |
| Operating CF Margin % | - | - | - | -15.9% | -359.91% |
| Operating CF Growth % | - | -171.43% | -339.09% | 98.16% | -3200.25% |
| Net Income | -2.54M | 8.7M | 3.79M | 13.56K | -1.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 2.45K | 104.73K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 4.09K | 26.58K |
| Other Non-Cash Items | 2.19M | -10.02M | -6.11M | 50.94K | 11.24K |
| Working Capital Changes | 90.42K | 632.18K | -697.49K | -126.7K | -567.81K |
| Change in Receivables | 0 | 0 | 0 | -63.86K | -11.02K |
| Change in Inventory | 0 | 0 | 0 | -30.57K | 28.52K |
| Change in Payables | 67.26K | 531.18K | -530.95K | 5.39K | 10.2K |
| Cash from Investing | -116.72M | -1.15M | 100.38M | -290 | -2.9M |
| Capital Expenditures | 0 | 0 | 0 | -290 | -74.91K |
| CapEx % of Revenue | - | - | - | 0.08% | 14.68% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 101.78M | 528.51K | -2.84M |
| Cash from Financing | 117.67M | 1.15M | -97.34M | 113.89K | 7.73M |
| Debt Issued (Net) | 0 | 1.15M | 4.2M | -32.61K | -32.98K |
| Equity Issued (Net) | 1000K | 0 | -1000K | 52.95K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -101.55M | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 93.54K | -99.56K |
| Net Change in Cash | 693.82K | -688.41K | 8.73K | 56.96K | 3.05M |
| Free Cash Flow | -253.62K | -688.42K | -3.02M | -55.95K | -4.75M |
| FCF Margin % | - | - | - | -15.98% | -930.29% |
| FCF Growth % | - | -171.44% | -339.08% | 98.15% | -8386.27% |
| FCF per Share | -0.02 | -0.05 | -0.33 | -0.00 | -1.15 |
| FCF Conversion (FCF/Net Income) | 0.10x | -0.08x | -0.80x | -4.10x | 1.30x |
| Interest Paid | 0 | 0 | 0 | 2.14K | 772 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -2.54% | 8.34% | 6.31% | 0.24% | -42.69% |
| Return on Invested Capital (ROIC) | - | -1.24% | -2.9% | -0.13% | -63.31% |
| Gross Margin | - | - | - | 43.82% | 30.44% |
| Net Margin | - | - | - | 3.87% | -276.58% |
| Debt / Equity | - | - | - | 2.07x | 0.00x |
| Interest Coverage | - | - | - | -4.59x | -1893.69x |
| FCF Conversion | 0.10x | -0.08x | -0.80x | -4.10x | 1.30x |
| Revenue Growth | - | - | - | - | 45.76% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics